Metaproteomics as a Complementary Approach to Gut Microbiota in Health and Disease

Classic studies on phylotype profiling are limited to the identification of microbial constituents, where information is lacking about the molecular interaction of these bacterial communities with the host genome and the possible outcomes in host biology. A range of OMICs approaches have provided great progress linking the microbiota to health and disease. However, the investigation of this context through proteomic mass spectrometry-based tools is still being improved. Therefore, metaproteomics or community proteogenomics has emerged as a complementary approach to metagenomic data, as a field in proteomics aiming to perform large-scale characterization of proteins from environmental microbiota, such as the human gut. The advances in molecular separation methods coupled with mass spectrometry (e.g., LC-MS/MS) and proteome bioinformatics have been fundamental in these novel large-scale metaproteomic studies, which have further been performed in a wide range of samples including soil, plant and human environments. Metaproteomic studies will make major progress if a comprehensive database covering the genes and expresses proteins from all gut microbial species is developed. To this end, we here present some of the main limitations of metaproteomic studies in complex microbiota environments, such as the gut, also addressing the up-to-date pipelines in sample preparation prior to fractionation/separation and mass spectrometry analysis. In addition, a novel approach to the limitations of metagenomic databases is also discussed. Finally, prospects are addressed regarding the application of metaproteomic analysis using a unified host-microbiome gene database and other meta-OMICs platforms.

[1]  Chongle Pan,et al.  Microbial metaproteomics for characterizing the range of metabolic functions and activities of human gut microbiota , 2015, Proteomics.

[2]  Daniel Y. Li,et al.  Listening to Our Gut: Contribution of Gut Microbiota and Cardiovascular Risk in Diabetes Pathogenesis , 2015, Current Diabetes Reports.

[3]  Jun Wang,et al.  Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota , 2015, Nature.

[4]  Brian J. Bennett,et al.  Transmission of Atherosclerosis Susceptibility with Gut Microbial Transplantation* , 2014, The Journal of Biological Chemistry.

[5]  W. Garrett,et al.  A complex microworld in the gut: Gut microbiota and cardiovascular disease connectivity , 2012, Nature Medicine.

[6]  Joel A. Kooren,et al.  A two‐step database search method improves sensitivity in peptide sequence matches for metaproteomics and proteogenomics studies , 2013, Proteomics.

[7]  T. Graeber,et al.  A Metaproteomic Approach to Study Human-Microbial Ecosystems at the Mucosal Luminal Interface , 2011, PloS one.

[8]  J. Clemente,et al.  Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice , 2013, Science.

[9]  J. Grivel,et al.  Use of human tissue explants to study human infectious agents , 2009, Nature Protocols.

[10]  R. Heyer,et al.  Metaproteomics of activated sludge from a wastewater treatment plant – A pilot study , 2015, Proteomics.

[11]  I. Martínez,et al.  Challenges of metabolomics in human gut microbiota research. , 2016, International journal of medical microbiology : IJMM.

[12]  G. Lopaschuk,et al.  Gut microbiota metabolism of L-carnitine and cardiovascular risk. , 2013, Atherosclerosis.

[13]  S. Hazen,et al.  The contributory role of gut microbiota in cardiovascular disease. , 2014, The Journal of clinical investigation.

[14]  E. Diamandis Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool , 2004, Molecular & Cellular Proteomics.

[15]  P. Valet,et al.  Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota , 2011, Gut.

[16]  R. Aebersold,et al.  Mass spectrometry-based proteomics , 2003, Nature.

[17]  Massimo Deligios,et al.  A straightforward and efficient analytical pipeline for metaproteome characterization , 2014, Microbiome.

[18]  T. R. Licht,et al.  A catalog of the mouse gut metagenome , 2015, Nature Biotechnology.

[19]  P. Cosette,et al.  Proteomic analysis. , 2014, Methods in molecular biology.

[20]  E. Mardis,et al.  An obesity-associated gut microbiome with increased capacity for energy harvest , 2006, Nature.

[21]  P. Volchkov,et al.  Microbiota regulates type 1 diabetes through Toll-like receptors , 2015, Proceedings of the National Academy of Sciences.

[22]  S. Mazmanian,et al.  The gut microbiota shapes intestinal immune responses during health and disease , 2009, Nature Reviews Immunology.

[23]  Hui Sun,et al.  Mass spectrometry-based metabolomics: applications to biomarker and metabolic pathway research. , 2016, Biomedical chromatography : BMC.

[24]  Brandi L. Cantarel,et al.  Integrated Metagenomics/Metaproteomics Reveals Human Host-Microbiota Signatures of Crohn's Disease , 2012, PloS one.

[25]  F. Tinahones,et al.  Metabolomic insights into the intricate gut microbial–host interaction in the development of obesity and type 2 diabetes , 2015, Front. Microbiol..

[26]  A. Mira,et al.  Microbial mucosal colonic shifts associated with the development of colorectal cancer reveal the presence of different bacterial and archaeal biomarkers , 2015, Journal of Gastroenterology.

[27]  P. Turnbaugh,et al.  Microbial ecology: Human gut microbes associated with obesity , 2006, Nature.

[28]  J. Yates,et al.  Proteomic Analysis of Protein Turnover by Metabolic Whole Rodent Pulse-Chase Isotopic Labeling and Shotgun Mass Spectrometry Analysis. , 2016, Methods in molecular biology.

[29]  Vincent J. Denef,et al.  Strain-resolved community genomic analysis of gut microbial colonization in a premature infant , 2010, Proceedings of the National Academy of Sciences.

[30]  Adam Godzik,et al.  Shotgun metaproteomics of the human distal gut microbiota , 2008, The ISME Journal.

[31]  P. Wilmes,et al.  The application of two-dimensional polyacrylamide gel electrophoresis and downstream analyses to a mixed community of prokaryotic microorganisms. , 2004, Environmental microbiology.

[32]  James Butcher,et al.  MetaPro-IQ: a universal metaproteomic approach to studying human and mouse gut microbiota , 2016, Microbiome.

[33]  宁北芳,et al.  疟原虫var基因转换速率变化导致抗原变异[英]/Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A , 2005 .

[34]  Joshua E. Elias,et al.  Host-centric Proteomics of Stool: A Novel Strategy Focused on intestinal Responses to the Gut Microbiota* , 2013, Molecular & Cellular Proteomics.

[35]  Brian C. Thomas,et al.  Time series community genomics analysis reveals rapid shifts in bacterial species, strains, and phage during infant gut colonization , 2013, Genome research.

[36]  William A Ricke,et al.  Biomarker discovery in mass spectrometry‐based urinary proteomics , 2016, Proteomics. Clinical applications.

[37]  Petia Kovatcheva-Datchary,et al.  The Gut Microbiota , 2013 .

[38]  Massimo Deligios,et al.  Evaluating the Impact of Different Sequence Databases on Metaproteome Analysis: Insights from a Lab-Assembled Microbial Mixture , 2013, PloS one.

[39]  P. Bonfante,et al.  Soil metaproteomics reveals an inter-kingdom stress response to the presence of black truffles , 2016, Scientific Reports.

[40]  Jens Roat Kultima,et al.  Disentangling the effects of type 2 diabetes and metformin on the human gut microbiota , 2015, Nature.

[41]  Paul Wilmes,et al.  A decade of metaproteomics: Where we stand and what the future holds , 2015, Proteomics.

[42]  Paul M. Ruegger,et al.  Host–microbe relationships in inflammatory bowel disease detected by bacterial and metaproteomic analysis of the mucosal–luminal interface , 2012, Inflammatory bowel diseases.

[43]  Nico Jehmlich,et al.  Proteomic interrogation of the gut microbiota: potential clinical impact , 2016, Expert review of proteomics.

[44]  Judith Aron-Wisnewsky,et al.  The gut microbiome, diet, and links to cardiometabolic and chronic disorders , 2016, Nature Reviews Nephrology.

[45]  W. D. de Vos,et al.  Comparative Metaproteomics and Diversity Analysis of Human Intestinal Microbiota Testifies for Its Temporal Stability and Expression of Core Functions , 2012, PloS one.

[46]  V. Jala,et al.  Evidence for a link between gut microbiota and hypertension in the Dahl rat. , 2015, Physiological genomics.

[47]  M. Rescigno,et al.  Probiotic and postbiotic activity in health and disease: comparison on a novel polarised ex-vivo organ culture model , 2012, Gut.

[48]  Andrew I. Su,et al.  A comprehensive and scalable database search system for metaproteomics , 2016, BMC Genomics.

[49]  Paul Wilmes,et al.  From meta-omics to causality: experimental models for human microbiome research , 2013, Microbiome.

[50]  Fuhao Zou,et al.  Type 2 Diabetes Biomarkers of Human Gut Microbiota Selected via Iterative Sure Independent Screening Method , 2015, PloS one.

[51]  Richard J. Giannone,et al.  Development of an Enhanced Metaproteomic Approach for Deepening the Microbiome Characterization of the Human Infant Gut , 2014, Journal of proteome research.

[52]  O. Franco,et al.  Exercise induction of gut microbiota modifications in obese, non-obese and hypertensive rats , 2014, BMC Genomics.

[53]  D. T. Wong,et al.  Large‐scale identification of proteins in human salivary proteome by liquid chromatography/mass spectrometry and two‐dimensional gel electrophoresis‐mass spectrometry , 2005, Proteomics.

[54]  Jens Roat Kultima,et al.  An integrated catalog of reference genes in the human gut microbiome , 2014, Nature Biotechnology.

[55]  K. Riedel,et al.  Environmental proteomics: Analysis of structure and function of microbial communities , 2010, Proteomics.

[56]  O. Franco,et al.  NanoUPLC/MS(E) proteomic analysis reveals modulation on left ventricle proteome from hypertensive rats after exercise training. , 2015, Journal of proteomics.